TCR2
A development stage company focusing on development of biological drugs and engineering T cells for cancer therapy.
Launch date
Employees
Market cap
CAD79.2m
Enterprise valuation
(CAD63m) (Public information from Jun 2023)
Share price
$1.48 TCRR
Cambridge Massachusetts (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| EBITDA | (12.9m) | (26.0m) | (50.5m) | (67.1m) | (93.3m) | (120m) |
| Profit | (13.1m) | (24.3m) | (47.6m) | (67.1m) | (99.8m) | (152m) |
| R&D budget | 9.6m | 19.7m | 37.5m | 52.0m | 73.6m | 98.6m |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Early VC | ||
| N/A | $3.8m | Series A | |
$44.5m | Series A | ||
$125m | Series B | ||
| N/A | N/A | IPO | |
* | N/A | $124m | Post IPO Equity |
* | N/A | Acquisition | |
| Total Funding | CAD236m | ||
Related Content
Recent News about TCR2
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.